AngioDynamics (NASDAQ:ANGO) Releases FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of -0.340–0.310 for the period, compared to the consensus EPS estimate of -0.370. The company issued revenue guidance of $285.0 million-$288.0 million, compared to the consensus revenue estimate of $284.9 million.

AngioDynamics Trading Up 2.9 %

ANGO opened at $9.66 on Wednesday. AngioDynamics has a 12-month low of $5.47 and a 12-month high of $13.50. The business’s fifty day simple moving average is $10.30 and its 200-day simple moving average is $8.84. The company has a market capitalization of $390.90 million, a price-to-earnings ratio of -1.72 and a beta of 0.56.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. On average, equities research analysts predict that AngioDynamics will post -0.37 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright boosted their price target on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

Insider Transactions at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now directly owns 41,817 shares in the company, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.40% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.